European Medicines Agency started the review of the chinese vaccine!

Following the Sputnik vaccine, the EMA is also reviewing the Chinese coronavirus vaccine, Sinovac. Initial data from laboratory studies show that according to the EMA this vaccine does produce an immune response. This review allows EU regulators to evaluate this data, as soon as it becomes accessible, by the time it is considered as sufficient evidence for a formal authorization for use.

The EMA did not give a timeline for its final decision, but clarified that the verification process will take less time than usual, because some of the work has already been done during the first review. The European Medicines Agency is currently reviewing data on three other vaccines: Sputnik, Curevac RNA vaccine and Novavax protein-based vaccine.

The Sinovac vaccine uses an inactive virus, which cannot cause disease.
“We will see whether the Chinese vaccine meets the usual EMA standards in terms of efficacy, safety and quality,” the EMA said in a statement.The European Medicines Agency has approved four vaccines so far in the European Union: Pfizer / BioNTech, Moderna, Astrazeneca and Johnson & Johnson.